Oscar Health Reports Strong Q1 2026, Reaffirms Guidance – But Risk Adjustment Uncertainty Persists

What happened

Oscar Health announced strong Q1 2026 results and reaffirmed its full-year guidance, which targets MLR improvement to 82.4%-83.4% and operating earnings of $250M-$450M. The company's press release comes after a year of repeated upward revisions to risk adjustment payables due to higher-than-expected market morbidity. While management expressed confidence in the 2026 outlook, the DeepValue Master Report emphasizes that the investment case hinges on observable proof that risk adjustment accruals stabilize and quarterly MLR trends into the low-80s. The reaffirmation does not resolve the fundamental risk that morbidity, subsidy expiration, or CMS integrity rules could pressure results. Investors must wait for the Q1 2026 10-Q to see if risk adjustment payables have finally stopped rising, a critical condition for the thesis to hold.

Implication

The Q1 results and reaffirmed guidance are consistent with management's narrative but provide no new evidence that the underwriting repair is on track. The DeepValue report's thesis breakers remain intact: if the Q1 10-Q shows another risk adjustment payable increase or if 1H26 MLR does not trend toward 82-83%, the investment case fails. The stock at ~$13.51 prices in high confidence in guidance, yet filings show repeated estimation errors in 2025. Enhanced subsidy expiration and program integrity enforcement add downside risk not reflected in the price. Therefore, waiting for concrete evidence of stabilization before building a position is the prudent course.

Thesis delta

The reaffirmation of guidance is a neutral data point that does not alter the thesis. The critical test remains whether Q1 2026 filings confirm stabilization of risk adjustment payables and MLR improvement. Until then, the WAIT rating is appropriate, and the stock lacks a margin of safety.